Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

Jorge E. Cortes, Bogdan Muresan, Carla Mamolo, Joseph C. Cappelleri, Rocco J. Crescenzo, Yun Su, Carlo Gambacorti-Passerini, Bart Heeg, B. Douglas Smith

Research output: Contribution to journalArticle

Abstract

Objective: In clinical trials of second-line therapies for chronic phase chronic myeloid leukemia (CP-CML), to date, only single-arm trials have been conducted for the available tyrosine kinase inhibitor treatments (bosutinib, dasatinib and nilotinib). These trials included heterogeneous patient populations in terms of disease and baseline characteristics. These hamper the use of standard network meta-analyses for indirect treatment comparison of relative efficacy. In this situation, a matching-adjusted indirect comparison (MAIC) in second-line CP-CML was performed. The aim was to compare the relative efficacies of bosutinib, dasatinib and nilotinib in second-line CP-CML patients. Methods: The MAIC was preceded by a systematic literature review that ensured inclusion of the underlying data for the analyses. The outcomes were measured in terms of overall survival (OS), progression-free survival (PFS) and major cytogenetic response (MCyR). The treatments were quantitatively compared based on Cox proportional hazard ratio (HR) regressions, on restricted mean survival (RMST, when the proportionality assumption showed evidence of violation) and on odds ratios (for response measures). Results: Comparing with dasatinib, bosutinib resulted in HRs for PFS and OS of 0.63 (0.44–0.90, p <.05) and 0.82 (0.54–1.26, p =.37) respectively, and resulted in an OR for MCyR of 0.78 (0.53–1.16). Although the proportionality of hazards assumption was violated for PFS, the RMST analyses confirmed the findings of the Cox regression. When compared with nilotinib, bosutinib showed a significant HR of 0.54 (0.38–0.76, p <.01) in favor of bosutinib for PFS, a non-significant HR of 0.72 (0.46–1.13, p =.16) for OS and a non-significant OR of 0.98 (0.71–1.35) for MCyR. Conclusions: Bosutinib had a significantly greater PFS than both dasatinib and nilotinib. For OS, the findings were numerically in favor of bosutinib, but not statistically significant. For MCyR, the findings were numerically in favor of dasatinib and nilotinib, but not statistically significant.

Original languageEnglish (US)
Pages (from-to)1615-1622
Number of pages8
JournalCurrent Medical Research and Opinion
Volume35
Issue number9
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Disease-Free Survival
Survival
Therapeutics
Survival Analysis
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib
bosutinib
Protein-Tyrosine Kinases
Odds Ratio
Clinical Trials

Keywords

  • bosutinib
  • Chronic myeloid leukemia
  • chronic-phase
  • dasatinib
  • nilotinib

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. / Cortes, Jorge E.; Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C.; Crescenzo, Rocco J.; Su, Yun; Gambacorti-Passerini, Carlo; Heeg, Bart; Douglas Smith, B.

In: Current Medical Research and Opinion, Vol. 35, No. 9, 01.01.2019, p. 1615-1622.

Research output: Contribution to journalArticle

Cortes, Jorge E. ; Muresan, Bogdan ; Mamolo, Carla ; Cappelleri, Joseph C. ; Crescenzo, Rocco J. ; Su, Yun ; Gambacorti-Passerini, Carlo ; Heeg, Bart ; Douglas Smith, B. / Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. In: Current Medical Research and Opinion. 2019 ; Vol. 35, No. 9. pp. 1615-1622.
@article{b55a33baf71e4e659e42997ae66ce67f,
title = "Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia",
abstract = "Objective: In clinical trials of second-line therapies for chronic phase chronic myeloid leukemia (CP-CML), to date, only single-arm trials have been conducted for the available tyrosine kinase inhibitor treatments (bosutinib, dasatinib and nilotinib). These trials included heterogeneous patient populations in terms of disease and baseline characteristics. These hamper the use of standard network meta-analyses for indirect treatment comparison of relative efficacy. In this situation, a matching-adjusted indirect comparison (MAIC) in second-line CP-CML was performed. The aim was to compare the relative efficacies of bosutinib, dasatinib and nilotinib in second-line CP-CML patients. Methods: The MAIC was preceded by a systematic literature review that ensured inclusion of the underlying data for the analyses. The outcomes were measured in terms of overall survival (OS), progression-free survival (PFS) and major cytogenetic response (MCyR). The treatments were quantitatively compared based on Cox proportional hazard ratio (HR) regressions, on restricted mean survival (RMST, when the proportionality assumption showed evidence of violation) and on odds ratios (for response measures). Results: Comparing with dasatinib, bosutinib resulted in HRs for PFS and OS of 0.63 (0.44–0.90, p <.05) and 0.82 (0.54–1.26, p =.37) respectively, and resulted in an OR for MCyR of 0.78 (0.53–1.16). Although the proportionality of hazards assumption was violated for PFS, the RMST analyses confirmed the findings of the Cox regression. When compared with nilotinib, bosutinib showed a significant HR of 0.54 (0.38–0.76, p <.01) in favor of bosutinib for PFS, a non-significant HR of 0.72 (0.46–1.13, p =.16) for OS and a non-significant OR of 0.98 (0.71–1.35) for MCyR. Conclusions: Bosutinib had a significantly greater PFS than both dasatinib and nilotinib. For OS, the findings were numerically in favor of bosutinib, but not statistically significant. For MCyR, the findings were numerically in favor of dasatinib and nilotinib, but not statistically significant.",
keywords = "bosutinib, Chronic myeloid leukemia, chronic-phase, dasatinib, nilotinib",
author = "Cortes, {Jorge E.} and Bogdan Muresan and Carla Mamolo and Cappelleri, {Joseph C.} and Crescenzo, {Rocco J.} and Yun Su and Carlo Gambacorti-Passerini and Bart Heeg and {Douglas Smith}, B.",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/03007995.2019.1605239",
language = "English (US)",
volume = "35",
pages = "1615--1622",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

AU - Cortes, Jorge E.

AU - Muresan, Bogdan

AU - Mamolo, Carla

AU - Cappelleri, Joseph C.

AU - Crescenzo, Rocco J.

AU - Su, Yun

AU - Gambacorti-Passerini, Carlo

AU - Heeg, Bart

AU - Douglas Smith, B.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: In clinical trials of second-line therapies for chronic phase chronic myeloid leukemia (CP-CML), to date, only single-arm trials have been conducted for the available tyrosine kinase inhibitor treatments (bosutinib, dasatinib and nilotinib). These trials included heterogeneous patient populations in terms of disease and baseline characteristics. These hamper the use of standard network meta-analyses for indirect treatment comparison of relative efficacy. In this situation, a matching-adjusted indirect comparison (MAIC) in second-line CP-CML was performed. The aim was to compare the relative efficacies of bosutinib, dasatinib and nilotinib in second-line CP-CML patients. Methods: The MAIC was preceded by a systematic literature review that ensured inclusion of the underlying data for the analyses. The outcomes were measured in terms of overall survival (OS), progression-free survival (PFS) and major cytogenetic response (MCyR). The treatments were quantitatively compared based on Cox proportional hazard ratio (HR) regressions, on restricted mean survival (RMST, when the proportionality assumption showed evidence of violation) and on odds ratios (for response measures). Results: Comparing with dasatinib, bosutinib resulted in HRs for PFS and OS of 0.63 (0.44–0.90, p <.05) and 0.82 (0.54–1.26, p =.37) respectively, and resulted in an OR for MCyR of 0.78 (0.53–1.16). Although the proportionality of hazards assumption was violated for PFS, the RMST analyses confirmed the findings of the Cox regression. When compared with nilotinib, bosutinib showed a significant HR of 0.54 (0.38–0.76, p <.01) in favor of bosutinib for PFS, a non-significant HR of 0.72 (0.46–1.13, p =.16) for OS and a non-significant OR of 0.98 (0.71–1.35) for MCyR. Conclusions: Bosutinib had a significantly greater PFS than both dasatinib and nilotinib. For OS, the findings were numerically in favor of bosutinib, but not statistically significant. For MCyR, the findings were numerically in favor of dasatinib and nilotinib, but not statistically significant.

AB - Objective: In clinical trials of second-line therapies for chronic phase chronic myeloid leukemia (CP-CML), to date, only single-arm trials have been conducted for the available tyrosine kinase inhibitor treatments (bosutinib, dasatinib and nilotinib). These trials included heterogeneous patient populations in terms of disease and baseline characteristics. These hamper the use of standard network meta-analyses for indirect treatment comparison of relative efficacy. In this situation, a matching-adjusted indirect comparison (MAIC) in second-line CP-CML was performed. The aim was to compare the relative efficacies of bosutinib, dasatinib and nilotinib in second-line CP-CML patients. Methods: The MAIC was preceded by a systematic literature review that ensured inclusion of the underlying data for the analyses. The outcomes were measured in terms of overall survival (OS), progression-free survival (PFS) and major cytogenetic response (MCyR). The treatments were quantitatively compared based on Cox proportional hazard ratio (HR) regressions, on restricted mean survival (RMST, when the proportionality assumption showed evidence of violation) and on odds ratios (for response measures). Results: Comparing with dasatinib, bosutinib resulted in HRs for PFS and OS of 0.63 (0.44–0.90, p <.05) and 0.82 (0.54–1.26, p =.37) respectively, and resulted in an OR for MCyR of 0.78 (0.53–1.16). Although the proportionality of hazards assumption was violated for PFS, the RMST analyses confirmed the findings of the Cox regression. When compared with nilotinib, bosutinib showed a significant HR of 0.54 (0.38–0.76, p <.01) in favor of bosutinib for PFS, a non-significant HR of 0.72 (0.46–1.13, p =.16) for OS and a non-significant OR of 0.98 (0.71–1.35) for MCyR. Conclusions: Bosutinib had a significantly greater PFS than both dasatinib and nilotinib. For OS, the findings were numerically in favor of bosutinib, but not statistically significant. For MCyR, the findings were numerically in favor of dasatinib and nilotinib, but not statistically significant.

KW - bosutinib

KW - Chronic myeloid leukemia

KW - chronic-phase

KW - dasatinib

KW - nilotinib

UR - http://www.scopus.com/inward/record.url?scp=85065976067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065976067&partnerID=8YFLogxK

U2 - 10.1080/03007995.2019.1605239

DO - 10.1080/03007995.2019.1605239

M3 - Article

C2 - 30964361

AN - SCOPUS:85065976067

VL - 35

SP - 1615

EP - 1622

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 9

ER -